Skip to content

Rufinamide

    Brands

    DEA Class;  Rx

    Common Brand Names; Banzel

    • Anticonvulsants,Others

    Triazole derivative anticonvulsant
    Used for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
    Approved for use in patients >= 1 year

    Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

    For the adjunctive treatment of refractory partial seizures.

    Documented hypersensitivity

    Familial Short QT syndrome

    Diplopia

    Dizziness

    Fatigue

    Headache

    Somnolence

    Nausea

    Vomiting

    Steven’s-Johnson syndrome

    Shortens QT interval

    Not recommended in severe hepatic impairment

    Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity, reported in patients taking antiepileptic drugs, including rufinamide; DRESS may be fatal or life-threatening; if DRESS suspected, evaluate patient immediately; discontinue therapy and initiate alternative treatment

    Withdraw gradually

    May impair ability to drive or perform hazardous tasks

    May render hormonal contraceptives ineffective

    Data are unavailable on the developmental risk associated with use in pregnant women

    Data are not available regarding rufinamide presence in human milk, effects on breastfed infants, or effects on milk production

    Adults

    3200 mg/day PO.

    Geriatric

    3200 mg/day PO.

    Adolescents

    17 years: 3200 mg/day PO.
    13—16 years: 45 mg/kg/day PO (Max: 3200 mg/day).

    Children

    45 mg/kg/day PO (Max: 3200 mg/day).

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Rufinamide

    tablet

    • 200mg
    • 400mg

    oral suspension

    • 40mg/mL